Denali Therapeutics: AVLAYAH revenue reaches $17.8M in Q3 2026, Q4 guidance $30.0-32.0M
FROM THE WIRE · GLOBENEWSWIRE.COM
AVLAYAH® (tividenofusp alfa-eknm) net product revenue accelerated to $17.8 million in its second full commercial quarter Continued growth expectations drive Q4 2026 net product revenue guidance of $30.0 million to $32.0 million AVLAYAH recognized as the “Best Biotechnology…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishAccelerating product revenue and Q4 guidance matter for the stock, while net income includes a one-time gain on a voucher sale.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01AVLAYAH net product revenue accelerated to $17.8 million in its second full commercial quarter.
- 02Q4 2026 net product revenue guidance is $30.0 million to $32.0 million.
- 03Q3 2026 net income of $70.1 million included a one-time $194.0 million gain on the sale of a Priority Review Voucher.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets